Dynavax Technologies Corp., of Berkeley, Calif., said it intends to offer $125 million of shares of its common stock, subject to market and other conditions, in an underwritten public offering. The company also expects to grant the underwriters a 30-day option to purchase up to an additional $18.75 million of shares of its common stock to cover overallotments, if any. Net proceeds from the proposed offering will support activities associated with preparing for their anticipated U.S. commercial launch of Heplisav-B if it gains FDA approval. Also the funds will support continuing the clinical development of lead investigational cancer immunotherapeutic product candidates, SD-101 and DV-281.